160 related articles for article (PubMed ID: 29604543)
1. Design, synthesis and activity of BBI608 derivatives targeting on stem cells.
Zhou Q; Peng C; Du F; Zhou L; Shi Y; Du Y; Liu D; Sun W; Zhang M; Chen G
Eur J Med Chem; 2018 May; 151():39-50. PubMed ID: 29604543
[TBL] [Abstract][Full Text] [Related]
2. A novel series of napabucasin derivatives as orally active inhibitors of signal transducer and activator of transcription 3 (STAT3).
Li C; Chen C; An Q; Yang T; Sang Z; Yang Y; Ju Y; Tong A; Luo Y
Eur J Med Chem; 2019 Jan; 162():543-554. PubMed ID: 30472602
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis and biological evaluation of novel potent STAT3 inhibitors based on BBI608 for cancer therapy.
Feng KR; Wang F; Shi XW; Tan YX; Zhao JY; Zhang JW; Li QH; Lin GQ; Gao D; Tian P
Eur J Med Chem; 2020 Sep; 201():112428. PubMed ID: 32603980
[TBL] [Abstract][Full Text] [Related]
4. Suppression of cancer relapse and metastasis by inhibiting cancer stemness.
Li Y; Rogoff HA; Keates S; Gao Y; Murikipudi S; Mikule K; Leggett D; Li W; Pardee AB; Li CJ
Proc Natl Acad Sci U S A; 2015 Feb; 112(6):1839-44. PubMed ID: 25605917
[TBL] [Abstract][Full Text] [Related]
5. 2-Ethoxystypandrone, a novel small-molecule STAT3 signaling inhibitor from Polygonum cuspidatum, inhibits cell growth and induces apoptosis of HCC cells and HCC Cancer stem cells.
Li W; Zhang Q; Chen K; Sima Z; Liu J; Yu Q; Liu J
BMC Complement Altern Med; 2019 Feb; 19(1):38. PubMed ID: 30709346
[TBL] [Abstract][Full Text] [Related]
6. Napabucasin: An Update on the First-in-Class Cancer Stemness Inhibitor.
Hubbard JM; Grothey A
Drugs; 2017 Jul; 77(10):1091-1103. PubMed ID: 28573435
[TBL] [Abstract][Full Text] [Related]
7. BBI608 inhibits cancer stemness and reverses cisplatin resistance in NSCLC.
MacDonagh L; Gray SG; Breen E; Cuffe S; Finn SP; O'Byrne KJ; Barr MP
Cancer Lett; 2018 Aug; 428():117-126. PubMed ID: 29653268
[TBL] [Abstract][Full Text] [Related]
8. Napabucasin (BBI608) eliminate AML cells in vitro and in vivo via inhibition of Stat3 pathway and induction of DNA damage.
Bi S; Chen K; Feng L; Fu G; Yang Q; Deng M; Zhao H; Li Z; Yu L; Fang Z; Xu B
Eur J Pharmacol; 2019 Jul; 855():252-261. PubMed ID: 31085238
[TBL] [Abstract][Full Text] [Related]
9. Napabucasin and Related Heterocycle-Fused Naphthoquinones as STAT3 Inhibitors with Antiproliferative Activity against Cancer Cells.
Löcken H; Clamor C; Müller K
J Nat Prod; 2018 Jul; 81(7):1636-1644. PubMed ID: 30003778
[TBL] [Abstract][Full Text] [Related]
10. Design, synthesis and biological evaluation of novel plumbagin derivatives as potent antitumor agents with STAT3 inhibition.
Li N; Ou J; Bao N; Chen C; Shi Z; Chen L; Sun J
Bioorg Chem; 2020 Nov; 104():104208. PubMed ID: 32919131
[TBL] [Abstract][Full Text] [Related]
11. Identification of New Shikonin Derivatives as Antitumor Agents Targeting STAT3 SH2 Domain.
Qiu HY; Zhu X; Luo YL; Lin HY; Tang CY; Qi JL; Pang YJ; Yang RW; Lu GH; Wang XM; Yang YH
Sci Rep; 2017 Jun; 7(1):2863. PubMed ID: 28588262
[TBL] [Abstract][Full Text] [Related]
12. The Use of Naphthoquinones and Furano-naphthoquinones as Antiinvasive Agents.
Tsang NY; Chik WI; Sze LP; Wang MZ; Tsang SW; Zhang HJ
Curr Med Chem; 2018; 25(38):5007-5056. PubMed ID: 28990521
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.
Xie R; Yao Y; Tang P; Chen G; Liu X; Yun F; Cheng C; Wu X; Yuan Q
Eur J Med Chem; 2017 Jul; 134():1-12. PubMed ID: 28391133
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis and activity of novel 2,6-disubstituted purine derivatives, potential small molecule inhibitors of signal transducer and activator of transcription 3.
Wang X; He Q; Wu K; Guo T; Du X; Zhang H; Fang L; Zheng N; Zhang Q; Ye F
Eur J Med Chem; 2019 Oct; 179():218-232. PubMed ID: 31254923
[TBL] [Abstract][Full Text] [Related]
15. Synthesis of Spirooxindole-O-Naphthoquinone-Tetrazolo[1,5-a]Pyrimidine Hybrids as Potential Anticancer Agents.
Wu L; Liu Y; Li Y
Molecules; 2018 Sep; 23(9):. PubMed ID: 30213123
[TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and biological evaluation of 3-(1-benzotriazole)-nor-β-lapachones as NQO1-directed antitumor agents.
Wu LQ; Ma X; Liu ZP
Bioorg Chem; 2021 Aug; 113():104995. PubMed ID: 34034133
[TBL] [Abstract][Full Text] [Related]
17. STAT3 inhibition induces Bax-dependent apoptosis in liver tumor myeloid-derived suppressor cells.
Guha P; Gardell J; Darpolor J; Cunetta M; Lima M; Miller G; Espat NJ; Junghans RP; Katz SC
Oncogene; 2019 Jan; 38(4):533-548. PubMed ID: 30158673
[TBL] [Abstract][Full Text] [Related]
18. Antiproliferative activities and SAR studies of substituted anthraquinones and 1,4-naphthoquinones.
Bhasin D; Etter JP; Chettiar SN; Mok M; Li PK
Bioorg Med Chem Lett; 2013 Dec; 23(24):6864-7. PubMed ID: 24176397
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of naphthoquinone derivatives as antiproliferative agents and 20S proteasome inhibitors.
Xu K; Xiao Z; Tang YB; Huang L; Chen CH; Ohkoshi E; Lee KH
Bioorg Med Chem Lett; 2012 Apr; 22(8):2772-4. PubMed ID: 22437113
[TBL] [Abstract][Full Text] [Related]
20. Nucleus-Targeted, Echogenic Polymersomes for Delivering a Cancer Stemness Inhibitor to Pancreatic Cancer Cells.
Karandish F; Mamnoon B; Feng L; Haldar MK; Xia L; Gange KN; You S; Choi Y; Sarkar K; Mallik S
Biomacromolecules; 2018 Oct; 19(10):4122-4132. PubMed ID: 30169024
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
